Several reports have revealed that the duration from treatment to ICI-induced hypopituitarism was shorter in patients treated with anti-CTLA-4 mAb therapy or combination therapy with ICIs than in those who received anti-PD-1 mAb therapy [9, 10]. Here, CTLA4 is linked to hypopituitarism.